Direct evidence for the critical role of NFAT3 in benzo[a]pyrene diol-epoxide-induced cell transformation through mediation of inflammatory cytokine TNF induction in mouse epidermal Cl41 cells

Carcinogenesis

Volumn 28, Issue 10, 2007, Pages 2218-2226

  Ouyang, Weiming ^a   Hu, Yu ^a   Li, Jingxia ^a   Ding, Min ^b   Lu, Yongju ^b   Zhang, Dongyun ^a   Yan, Yan ^a   Song, Lun ^a   Qu, Qingshan ^a   Desai, Dhimant ^c   Amin, Shantu ^c   Huang, Chuanshu ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; DIHYDROXYBENZO[A]PYRENE OXIDE; SMALL INTERFERING RNA; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL TRANSFORMATION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; EPIDERMIS CELL; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SKIN CARCINOGENESIS; UPREGULATION;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; ANIMALS; CELL DIVISION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; EPIDERMIS; FEMALE; GENES, REPORTER; GENETIC VECTORS; MICE; MICE, NUDE; NFATC TRANSCRIPTION FACTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35148855014     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm115     Document Type: Article

References (74)

1. IARC (1983) Polynuclear aromatic compounds, part 1: Chemical, environmental and experimental data. In: Evaluation of the Carcinogenic Risk of Chemicals to Humans. 32, 1-453 IARC Monographs, Lyon.
2. Phillips,D.H. (1983) Fifty years of benzo(a)pyrene. Nature, 303 468-472.
3. Bostrom,C.E. et al. (2002) Cancer risk assessment, indicators, and guidelines for polycyclic aromatic hydrocarbons in the ambient air. Environ. Health Perspect., 110 (Suppl. 3), 451-488.
4. Sims,P. et al. (1974) Epoxides in polycyclic aromatic hydrocarbon metabolism and carcinogenesis. Adv. Cancer Res., 20, 165-274.
5. Denissenko,M.F. et al. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science, 274, 430-432.
6. Merimsky,O. et al. (1998) Cigarette smoking and skin cancer. Clin. Dermatol., 16, 585-588.
7. Hecker,E. (1987) Three stage carcinogenesis in mouse skin - recent results and present status of an advanced model system of chemical carcinogenesis. Toxicol. Pathol., 15, 245-258.
8. Zoumpourlis,V. et al. (2003) Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis. Carcinogenesis, 24, 1159-1165.
9. Fahl,W.E. et al. (1981) Relationship between benzo(a)pyrene-induced DNA base modification and frequency of reverse mutations in mutant strains of Salmonella typhimurium. Cancer Res. 41, 3400-3406.
10. Cai,Y. et al. (1997) Effect of naturally occurring coumarins on the formation of epidermal DNA adducts and skin tumors induced by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in SENCAR mice. Carcinogenesis, 18, 1521-1527.
11. Nakayama,J. et al. (1984) Benzo(a)pyrene-DNA adduct formation and removal in mouse epidermis in vivo and in vitro: relationship of DNA binding to initiation of skin carcinogenesis. Cancer Res., 44, 4087-4095.
12. Albert,R.E. et al. (1991) Benzo[a]pyrene-induced skin damage and tumor promotion in the mouse. Carcinogenesis, 12, 1273-1280.
13. Coussens,L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860-867.
14. Locksley,R.M. et al. (2001) The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell, 104, 487-501.
15. Malik,S. et al. (1988) The anti-cancer activity of tumour necrosis factor. Ann. Inst. Pasteur Immunol., 139, 285-288.
16. Szlosarek,P.W. et al. (2003) Tumour necrosis factor alpha: A potential target for the therapy of solid tumours. Lancet Oncol., 4, 565-573.
17. Moore,R.J. et al. (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med., 5 828-831.
18. Scott,K.A. et al. (2003) An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol. Cancer Ther., 2, 445-451.
19. Kitakata,H. et al. (2002) Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res., 62, 6682-6687.
20. Huang,C. et al. (1999) JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-alpha but not by 12-O-tetradecanoylphorbol-13-acetate. J. Biol. Chem., 274, 29672-29676.
21. Jain,J. et al. (1995) Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol., 7, 333-342.
22. Chow,C.W. et al. (1999) Requirement for transcription factor NFAT in interleukin-2 expression. Mol. Cell. Biol., 19, 2300-2307.
23. Rao,A. et al. (1997) Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol., 15, 707-747.
24. Cockerill,P.N. et al. (1993) The granulocyte-macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive enhancer. Proc. Natl. Acad. Sci. USA, 90, 2466-2470.
25. Shannon,M.F. et al. (1997) Signals for activation of the GM-CSF promoter and enhancer in T cells. Crit. Rev. Immunol., 17, 301-323.
26. McCaffrey,P.G. et al. (1994) The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription. J. Biol. Chem., 269, 30445-30450.
27. Iniguez,M.A. et al. (2000) An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J. Biol. Chem., 275, 23627-23635.
28. Li,J., Song,L., Zhang,D., Wei,L. and Huang,C. (2006) Knockdown of NFAT3 blocked TPA-induced COX-2 and iNOS expression, and enhanced cell transformation in C141 cells. J. Cell. Biochem, 99, 1010-1020.
29. Ding,J. et al. (2006) Nickel compounds render anti-apoptotic effect to human bronchial epithelial beas-2B cells by induction of cyclooxygenase-2 through an IKKbeta/p65-dependent and IKK{alpha}- and p50-independent pathway. J. Biol. Chem., 281, 39022-39032.
30. Colburn,N.H. et al. (1988) Transfer by pro gene transfection of tumor promoter-sensitive phenotype to promotion-insensitive JB6 cells. Cancer Res., 48, 1195-1200.
31. Li,J.J. et al. (1997) Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res., 57, 3569-3576.
32. Huang,C. et al. (1998) Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc. Natl Acad Sci. USA, 95 156-161.
33. Huang,C. et al. (2000) Involvement of nuclear factor of activated T cells activation in UV response. Evidence from cell culture and transgenic mice. J. Biol. Chem., 275, 9143-9149.
34. Rincon,M. et al. (1997) Transcription mediated by NFAT is highly inducible in effector CD4+ T helper 2 (Th2) cells but not in Th1 cells. Mol. Cell. Biol., 17, 1522-1534.
35. Zhang,X. et al. (2001) Rapid and sensitive assay of tumor necrosis factor-alpha gene transcription. Pharm. Res., 18, 408-411.
36. Huang,C. et al. (1996) Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P+ cells. Mol. Cell. Biol., 16, 6427-6435.
37. Huang,C. et al. (2002) Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C. Cancer Res., 62, 5689-5697.
38. Jungwirth,A. et al. (1997) Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc. Natl Acad. Sci. USA, 94, 5810-5813.
39. Brubaker,K.D. et al. (2006) Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer, 6, 15.
40. Li,J. et al. (2004) Differential effects of polycyclic aromatic hydrocarbons on transactivation of AP-1 and NF-kappaB in mouse epidermal cl41 cells. Mol. Carcinog., 40, 104-115.
41. Suganuma,M. et al. (1999) Essential role of tumor necrosis factor alpha TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res., 59, 4516-4518.
42. Chow,C.W. et al. (1997) Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science, 278, 1638-1641.
43. Li,J. et al. (2004) A critical role of PI-3K/Akt/JNKs pathways in benzo[a]pyrene diol-epoxide(B[a]PDE)-induced AP-1 transactivaiton in mouse epidermal Cl41 cells. Oncogene, 23, 3932-3944.
44. Lee,H. et al. (2005) NFATc3 deficiency may contribute to the development of mammary gland adenocarcinoma in aging female mice. Mol. Carcinog., 44, 219-222.
45. Huan,C. et al. (2001) Hydrogen peroxide mediates activation of nuclear factor of activated T cells (NFAT) by nickel subsulfide. Cancer Res., 61, 8051-8057.
46. Lu,H. et al. (2005) Carcinogenic effect of nickel compounds. Mol. Cell. Biochem., 279, 45-67.
47. Li,J. et al. (2002) Involvement of hydrogen peroxide in asbestos-induced NFAT activation. Mol. Cell. Biochem., 234-235 161-168.
48. Yarosh,D.B. et al. (2005) Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J. Invest. Dermatol., 125, 1020-1025.
49. Ding,J. et al. (2006) Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells. J. Biol. Chem., 281, 24405-24413.
50. Duque,J. et al. (2005) Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: Involvement in the regulation of cyclooxygenase-2. J. Biol. Chem., 280, 8686-8693.
51. Jimenez,J.L. et al. (2004) Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. Cell. Signal., 16, 1363-1373.
52. Lu,H. et al. (2006) Inflammation, a key event in cancer development. Mol. Cancer Res., 4, 221-233.
53. Flavell,R.A. (2002) The relationship of inflammation and initiation of autoimmune disease: Role of TNF super family members. Curr. Top. Microbiol. Immunol., 266, 1-9.
54. van Deventer,S.J. (1999) Review article: Targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease - the mechanisms of action of infliximab. Aliment. Pharmacol. Ther., 13 (Suppl. 4), 3-8 discussion 38.
55. Raza,A. (2000) Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. 50, 229-235.
56. Feldmann,M. et al. (2001) Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu. Rev. Immunol., 19, 163-196.
57. Philip,M. et al. (2004) Inflammation as a tumor promoter in cancer induction. Semin. Cancer Biol., 14, 433-439.
58. Klein,G. et al. (1985) Evolution of tumours and the impact of molecular oncology. Nature, 315, 190-195.
59. van der Woude,C.J. et al. (2004) Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. Apoptosis 9, 123-130.
60. Mayo,M.W. et al. (2000) The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta, 1470, M55-M562.
61. Pikarsky,E. et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431 461-466.
62. Arnott,C.H. et al. (2002) Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene, 21, 4728-4738.
63. Suzukawa,K. et al. (2002) AP-1, NF-kappa-B, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model. Environ. Health Perspect., 110, 865-870.
64. Scott,K.A. et al. (2004) TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene, 23, 6954-6966.
65. Tsai,E.Y. et al. (2000) A lipopolysaccharide-specific enhancer complex involving Ets, Elk-1, Sp1 and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo. Mol. Cell. Biol., 20, 6084-6094.
66. Falvo,J.V. et al. (2000) Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor alpha gene promoter. Mol. Cell. Biol., 20, 2239-2247
67. Tsai,E.Y. et al. (1996) Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol. Cell. Biol., 16, 459-467.
68. Song,L., Li,J., Ye,J., Yu,G., Ding,J. et al. (2006) p85α acts as a novel signal transducer specifically for cell apoptotic response to UV radiation. Mol. Cell. Biol, 27, 2713-2731.
69. Neal,J.W. et al. (2003) A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. J. Biol. Chem. 278, 17246-17254.
70. Jauliac,S. et al. (2002) The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat. Cell Biol., 4, 540-544.
71. Slaga,T.J. et al. (1979) Marked differences in the skin tumor-initiating activities of the optical enantiomers of the diastereomeric benzo(a)pyrene 7,8-diol-9,10-epoxides. Cancer Res., 39, 67-71.
72. Levin,W. et al. (1976) (+/-trans-7,8-dihydroxy-7,8-dihydrobenzo (a)pyrene: A potent skin carcinogen when applied topically to mice. Proc. Natl Acad. Sci. USA, 73, 3867-3871.
73. Bresnick,E. et al. (1977) Epidermal hyperplasia after topical application of benzo (a) pyrene, benzo (a) pyrene diol epoxides, and other metabolites. Cancer Res., 37, 984-990.
74. Li,J. et al. (2006) NFAT3 is required for EGF-induced COX-2 transcription, but neither iNOS transcription nor cell transformation in Cl 41 cells. Mol. Cell. Biochem., 289, 73.